周三，美银证券调整了对诺和诺德公司（NYSE:NVO）股票的展望，将目标价从之前的166.00美元下调至159.50美元，同时维持对该股票的买入评级。这一调整是因为分析师预计第三季度集团销售额将达到约694亿丹麦克朗，同比增长18%，息税前利润（EBIT）将达到约330亿丹麦克朗，较上年同期增长23%。尽管有这些增长，预测的EBIT比共识预期低约4%。

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...

Fourteen years ago, the older drug cousin of semaglutide (Ozempic and Wegovy) came onto the market. The drug, liraglutide, is ...

Christina Aguilera sparked heated debates over her dramatic weight loss. On September 26, the 43-year-old singer visited ...

As told to Alexia Dellner Weight loss drugs like Ozempic and Wegovy have become a hot topic of late, with everyone from ...

默沙东的肿瘤药物Keytruda ...

WeightWatchers' CEO of roughly two years, Sima Sistani, is out. She helped push the company into the white-hot weight-loss ...

周三，美银证券修改了全球医疗保健公司诺和诺德公司 (NOVOB:DC) (NYSE: NVO)的股票目标价。新的目标价被设定为DKK1,075.00，较此前的DKK1,150.00有所下调。尽管如此，该公司仍然维持对诺和诺德公司股票的买入评级。

Zmyra has become a standout natural alternative to Ozempic for weight loss. Reviewers for this article believe it to be the ...

She had her blonde hair tied up in a ponytail and finished the look with a pair of leather boots. The attendee who captured ...

Zmyra stands out as a potent natural over-the-counter alternative to Ozempic. It provides a comprehensive weight loss ...

Weight-loss drugs like Ozempic and Wegovy have become household names in recent years. But here's why they may not work for ...